News & Events about Neuronetics Inc.
MALVERN, Pa. and TORONTO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurological health disorders (...
Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxietyMALVERN, Pa., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing ...
Neuronetics, Inc. (NASDAQ:STIM Get Rating) major shareholder Cannell Capital Llc sold 141,664 shares of Neuronetics stock in a transaction that occurred on Monday, January 9th. The shares were sold at an average price of $6.59, for a total value of $933,565.76. Following the completion of ...
MALVERN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it has ...
MALVERN, Pa., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced certain ...